Journal Article

Tisagenlecleucel Is Safe and Effective in Relapsed/Refractory Follicular Lymphoma

Cancer discovery (2022) 12(3) OF4
DOI: 10.1158/2159-8290.CD-RW2022-004
2Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Tisagenlecleucel is safe and effective for adults with pretreated relapsed/refractory follicular lymphoma (FL).

Cite

CITATION STYLE

APA

Tisagenlecleucel Is Safe and Effective in Relapsed/Refractory Follicular Lymphoma. (2022). Cancer Discovery, 12(3), OF4. https://doi.org/10.1158/2159-8290.CD-RW2022-004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free